Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 3
2005 1
2006 1
2007 1
2008 2
2010 2
2011 1
2012 4
2013 1
2014 3
2015 5
2017 2
2018 1
2019 5
2020 4
2021 4
2022 3
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Olopade OI, Davis MB, Martin ML, Bargonetti J. Madorsky Rowdo FP, et al. Among authors: bargonetti j. Cancer Lett. 2024 Mar 1;584:216608. doi: 10.1016/j.canlet.2024.216608. Epub 2024 Jan 9. Cancer Lett. 2024. PMID: 38199587 Free article.
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Olopade OI, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Davis MB, Martin ML, Bargonetti J. Madorsky Rowdo FP, et al. Among authors: bargonetti j. bioRxiv [Preprint]. 2023 Jun 22:2023.06.22.544406. doi: 10.1101/2023.06.22.544406. bioRxiv. 2023. PMID: 38076873 Free PMC article. Updated. Preprint.
Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status.
Lama R, Xu C, Galster SL, Querol-García J, Portwood S, Mavis CK, Ruiz FM, Martin D, Wu J, Giorgi MC, Bargonetti J, Wang ES, Hernandez-Ilizaliturri FJ, Koudelka GB, Chemler SR, Muñoz IG, Wang X. Lama R, et al. Among authors: bargonetti j. Front Oncol. 2022 Aug 5;12:933446. doi: 10.3389/fonc.2022.933446. eCollection 2022. Front Oncol. 2022. PMID: 35992795 Free PMC article.
PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models.
Wilson T, Pirovano G, Xiao G, Samuels Z, Roberts S, Viray T, Guru N, Zanzonico P, Gollub M, Pillarsetty NVK, Reiner T, Bargonetti J. Wilson T, et al. Among authors: bargonetti j. Mol Pharm. 2021 Sep 6;18(9):3418-3428. doi: 10.1021/acs.molpharmaceut.1c00323. Epub 2021 Jul 28. Mol Pharm. 2021. PMID: 34318678 Free PMC article.
47 results